Selected research
Industry Research
Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Research Report 2026
Market perspective
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Severe Acute Respiratory Syndrome (SARS) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Severe Acute Respiratory Syndrome (SARS) Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Severe Acute Respiratory Syndrome (SARS) Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Severe Acute Respiratory Syndrome (SARS) Therapeutics include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Severe Acute Respiratory Syndrome (SARS) Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Company
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type
LCA-60
INO-4500
FDX-000
D-3252
CEL-1000
Others
Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application
Research Center
Hospital
Clinic
Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Severe Acute Respiratory Syndrome (SARS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Acute Respiratory Syndrome (SARS) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- LCA-60
- INO-4500
- FDX-000
- D-3252
- CEL-1000
- Others
Applications
- Research Center
- Hospital
- Clinic
Companies covered
- CEL-SCI Corporation
- GeneCure LLC
- Humabs BioMed SA
- Inovio Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- Novavax, Inc.
- Phelix Therapeutics, LLC
- Protein Sciences Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 LCA-60
- 2.2.3 INO-4500
- 2.2.4 FDX-000
- 2.2.5 D-3252
- 2.2.6 CEL-1000
- 2.2.7 Others
- 2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Research Center
- 2.3.3 Hospital
- 2.3.4 Clinic
- 2.4 Assumptions and Limitations
3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Type
- 3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2027-2032)
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Application
- 4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Perspective (2021-2032)
- 5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Growth Trends by Region
- 5.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
- 5.3.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
- 5.3.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
- 5.3.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
- 5.3.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue
- 6.1.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics Head Office and Area Served
- 6.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players, Product Type & Application
- 6.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Manufacturers Established Date
- 6.6 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
- 7.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
- 8.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
- 10.2 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 CEL-SCI Corporation
- 12.1.1 CEL-SCI Corporation Company Information
- 12.1.2 CEL-SCI Corporation Business Overview
- 12.1.3 CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.1.5 CEL-SCI Corporation Recent Developments
- 12.2 GeneCure LLC
- 12.2.1 GeneCure LLC Company Information
- 12.2.2 GeneCure LLC Business Overview
- 12.2.3 GeneCure LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.2.5 GeneCure LLC Recent Developments
- 12.3 Humabs BioMed SA
- 12.3.1 Humabs BioMed SA Company Information
- 12.3.2 Humabs BioMed SA Business Overview
- 12.3.3 Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.3.5 Humabs BioMed SA Recent Developments
- 12.4 Inovio Pharmaceuticals, Inc.
- 12.4.1 Inovio Pharmaceuticals, Inc. Company Information
- 12.4.2 Inovio Pharmaceuticals, Inc. Business Overview
- 12.4.3 Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
- 12.5 Nanotherapeutics, Inc.
- 12.5.1 Nanotherapeutics, Inc. Company Information
- 12.5.2 Nanotherapeutics, Inc. Business Overview
- 12.5.3 Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.5.5 Nanotherapeutics, Inc. Recent Developments
- 12.6 Novavax, Inc.
- 12.6.1 Novavax, Inc. Company Information
- 12.6.2 Novavax, Inc. Business Overview
- 12.6.3 Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.6.5 Novavax, Inc. Recent Developments
- 12.7 Phelix Therapeutics, LLC
- 12.7.1 Phelix Therapeutics, LLC Company Information
- 12.7.2 Phelix Therapeutics, LLC Business Overview
- 12.7.3 Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.7.5 Phelix Therapeutics, LLC Recent Developments
- 12.8 Protein Sciences Corporation
- 12.8.1 Protein Sciences Corporation Company Information
- 12.8.2 Protein Sciences Corporation Business Overview
- 12.8.3 Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2021-2026)
- 12.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
- 12.8.5 Protein Sciences Corporation Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst